BIOMAT Database Logo BIOMAT Database Logo

Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome. 1985

P A Volberding, and D I Abrams, and M Conant, and K Kaslow, and K Vranizan, and J Ziegler

Single-agent intravenous vinblastine, 4 to 8 mg/week, was used to treat 38 patients with Kaposi's sarcoma related to the acquired immunodeficiency syndrome. The dose was titrated in relation to the total leukocyte count. Ten patients had an objective response, and 19 had stable disease during therapy. Apart from expected modest neutropenia, toxicity was minimal. A lower response rate was seen in patients with anemia, an elevated erythrocyte sedimentation rate, or any lymphoma-like B symptom. Opportunistic infections were common regardless of type of response but were commoner in patients who did not respond. Vinblastine used in low doses weekly is effective in treating Kaposi's sarcoma related to the acquired immunodeficiency syndrome and has minimal associated toxicities.

UI MeSH Term Description Entries
D007239 Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases. Infection,Infection and Infestation,Infections and Infestations,Infestation and Infection,Infestations and Infections
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001799 Blood Sedimentation Measurement of rate of settling of ERYTHROCYTES in blood. Erythrocyte Sedimentation,Erythrocyte Sedimentation Rate,Erythrocyte Sedimentation Rates,Rate, Erythrocyte Sedimentation,Rates, Erythrocyte Sedimentation,Sedimentation Rate, Erythrocyte,Sedimentation Rates, Erythrocyte,Sedimentation, Blood,Sedimentation, Erythrocyte
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006400 Hematocrit The volume of packed RED BLOOD CELLS in a blood specimen. The volume is measured by centrifugation in a tube with graduated markings, or with automated blood cell counters. It is an indicator of erythrocyte status in disease. For example, ANEMIA shows a low value; POLYCYTHEMIA, a high value. Erythrocyte Volume, Packed,Packed Red-Cell Volume,Erythrocyte Volumes, Packed,Hematocrits,Packed Erythrocyte Volume,Packed Erythrocyte Volumes,Packed Red Cell Volume,Packed Red-Cell Volumes,Red-Cell Volume, Packed,Red-Cell Volumes, Packed,Volume, Packed Erythrocyte,Volume, Packed Red-Cell,Volumes, Packed Erythrocyte,Volumes, Packed Red-Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012514 Sarcoma, Kaposi A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause. Kaposi Sarcoma,Kaposi's Sarcoma,Multiple Idiopathic Pigmented Hemangiosarcoma,Kaposis Sarcoma,Sarcoma, Kaposi's

Related Publications

P A Volberding, and D I Abrams, and M Conant, and K Kaslow, and K Vranizan, and J Ziegler
Radiation therapy for acquired immunodeficiency syndrome-related Kaposi's sarcoma.
May 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
P A Volberding, and D I Abrams, and M Conant, and K Kaslow, and K Vranizan, and J Ziegler
Kaposi's sarcoma in the acquired immunodeficiency syndrome.
June 1988, Infectious disease clinics of North America,
P A Volberding, and D I Abrams, and M Conant, and K Kaslow, and K Vranizan, and J Ziegler
Acquired immunodeficiency syndrome-related Kaposi's sarcoma.
September 1995, Mayo Clinic proceedings,
P A Volberding, and D I Abrams, and M Conant, and K Kaslow, and K Vranizan, and J Ziegler
Acquired immunodeficiency syndrome and Kaposi's sarcoma.
February 1985, Journal of the Royal Society of Medicine,
P A Volberding, and D I Abrams, and M Conant, and K Kaslow, and K Vranizan, and J Ziegler
Kaposi's sarcoma--an acquired immunodeficiency syndrome.
February 1984, The Ohio State medical journal,
P A Volberding, and D I Abrams, and M Conant, and K Kaslow, and K Vranizan, and J Ziegler
Kaposi's sarcoma and the acquired immunodeficiency syndrome.
January 1984, The New Zealand medical journal,
P A Volberding, and D I Abrams, and M Conant, and K Kaslow, and K Vranizan, and J Ziegler
Kaposi's sarcoma and the acquired immunodeficiency syndrome.
May 1986, The Medical clinics of North America,
P A Volberding, and D I Abrams, and M Conant, and K Kaslow, and K Vranizan, and J Ziegler
Orbital Kaposi's sarcoma in acquired immunodeficiency syndrome.
January 2000, European journal of ophthalmology,
P A Volberding, and D I Abrams, and M Conant, and K Kaslow, and K Vranizan, and J Ziegler
Local therapy for mucocutaneous Kaposi's sarcoma in patients with acquired immunodeficiency syndrome.
March 1995, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],
P A Volberding, and D I Abrams, and M Conant, and K Kaslow, and K Vranizan, and J Ziegler
[Kaposi's sarcoma associated with acquired immunodeficiency syndrome].
January 1991, Journal des maladies vasculaires,
Copied contents to your clipboard!